HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper

This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Virus Eradication 2021-03, Vol.7 (1), p.100025
Main Authors: Fidler, S., Lewin, S., Deeks, S., Sogaard, O.S., Vanderkerckhove, L., Collins, S., Kelly, D., Singh, J., Caskey, M., Frater, J.
Format: Article
Language:English
Subjects:
Analytical treatment interruption (ATI) COVID-19
HIV cure
SARS-CoV-2
Viewpoint
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
ISSN:2055-6640
2055-6659
DOI:10.1016/j.jve.2020.100025